Arrowhead Pharmaceuticals, Inc.
ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial toā¦ read more
Healthcare
Biotechnology
30 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$28.89
Price+4.18%
$1.16
1Y
Price
Market Cap
$3.994b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$596.565m
-85.3%
1y CAGR-3.5%
3y CAGR+11.7%
5y CAGREarnings
-$148.417m
-129.3%
1y CAGR-57.0%
3y CAGR-59.4%
5y CAGREPS
-$1.30
-120.8%
1y CAGR-52.9%
3y CAGR-55.1%
5y CAGRBook Value
$517.299m
$1.381b
Assets$666.276m
Liabilities$112.700m
DebtDebt to Assets
8.2%
-0.9x
Debt to EBITDAFree Cash Flow
-$17.621m
-42.2%
1y CAGR-115.0%
3y CAGR-26.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company